Clinical trials: Survivor Patients
- Condition Survivor Patients
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
EGFR Mutation Positive Advanced Non-small-cell Lung Cancer
Gefitinib Long-term Survivor Study
The primary objective is to describe the genomic profile of long-term survivors, especially to find out potential genomic prognosis and/or predictive factors for gefitinib long-term efficacy as compared to rapid PD patients
- Trial name
- NCT02932345
- Where
- 14 sites in China
- Volunteers
- 59 people
- Sponsor
- AstraZeneca